The csf and plasma biomarker market is projected to grow from USD 3,229.4 million in 2026 to USD 6,655.8 million by 2036, at a CAGR of 7.5%. Neurodegenerative biomarkers will dominate with a 24.0% market share, while disease diagnosis will lead the applications segment with a 34.0% share.